Night one to two
Some older studies measured early subjective or EEG changes.
Protocol / Research Dosing Guide
DSIP Dosage Guide: Human Trial Context, Schedule and Safety
An evidence-organized Delta Sleep-Inducing Peptide reference separating small older IV trials from modern subcutaneous community protocols.
Last reviewed September 15, 202620 minute readResearch information only
Level 3 — Small older human trialsMixed sleep findingsNot FDA approved
DSIP Quick Start
DSIP is a nine-amino-acid peptide first isolated during sleep research. Small studies from the 1980s tested intravenous administration in insomnia, with mixed findings and no modern confirmatory program.
Why researchers care
Sleep architecture, stress, and neuroendocrine research
Class
Delta sleep-inducing nonapeptide; emideltide
Route reported
IV in older human trials; subcutaneous use is community reported
Cycle length
Four-to-seven-night trials; longer community cycles unvalidated
Regulatory status
Not FDA approved; FDA Category 2 compounding concern
Loading supplier information
DSIP Dosing Protocol and Schedule
Older studies used 25 nmol/kg IV for four to seven nights. The supplied source separately reports 100–300 mcg subcutaneous evening use; that modern pattern is community reported, not trial validated.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Older trials | 25 nmol/kg IV | Four to seven nights; study design |
| Community lower range | 100–200 mcg SC | Evening; not validated |
| Community higher range | 200–300 mcg SC | Evening; sparse safety data |
Trial IV amounts and community subcutaneous microgram amounts use different units and routes and are not interchangeable.
DSIP Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
DSIP Reconstitution Calculator
Vial-format concentration math
Concentration
5 mg/mL
Draw volume
0.02 mL
U-100 units
2
Mathematical draws
100
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take DSIP: Morning or Night?
One to three hours before sleep
Community reported, not established by a modern SC trial.
Short trial window
Older human studies evaluated several consecutive nights.
Longer cycles
Four-to-eight-week schedules are community planning only.
Missed amount
No validated procedure exists.
DSIP Route Comparison
| Route | Evidence context | Boundary |
|---|---|---|
| Intravenous | Small 1980s insomnia studies | Study setting only |
| Subcutaneous | Community reported | No validated clinical regimen |
| Oral or nasal | Not established | No validated exposure |
| Route conversion | Not established | nmol/kg IV cannot define SC mcg use |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
DSIP Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human half-life | Not established | No robust modern PK study |
| Bioavailability | Not established | No SC exposure study |
| Blood-brain transport | Preclinical context | No quantitative human PK |
| Frequency | Evening use is community reported | Not pharmacokinetically derived |
DSIP Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Intravenous | 25 nmol/kg | Four consecutive nights | Small human crossover study | Study design |
| Subcutaneous | 100–200 mcg | Once in evening | Community report | No |
| Subcutaneous | 200–300 mcg | Once in evening | Community report | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
DSIP Reconstitution Guide
Concentration: 5 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 0.1 mg | 0.02 mL | 2 units |
| 0.2 mg | 0.04 mL | 4 units |
| 0.3 mg | 0.06 mL | 6 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How DSIP Works
Sleep modulation
DSIP was named after early delta-wave observations, but its mechanism remains unresolved.
DSIP Human Trials and FDA Status
Current status · verified September 15, 2026
Not FDA approved; FDA Category 2 compounding concern
- A six-volunteer double-blind crossover study examined acute and delayed sleep effects after IV DSIP.
- A 16-person chronic-insomnia study used a double-blind matched-pairs design over five laboratory nights.
- A double-blind crossover study used 25 nmol/kg IV for four nights and found limited or inconsistent sleep effects.
- Other older studies reported modest sleep or daytime-function signals in very small samples.
- No modern large-sample confirmatory trial or approved indication exists.
Who Should Avoid DSIP?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data
Children or adolescents
No pediatric data
Untreated sleep apnea
Sleep symptoms require clinical assessment
Concurrent sedating medicines
Combined effects uncharacterized
Adrenal or thyroid disease
Neuroendocrine interactions uncertain
Substance withdrawal outside clinical care
Older reports do not support self-directed use
DSIP Side Effects, Risks and Safety
Headache, nausea, or dizzinessOlder human reports
Important limitation: Small datasets.
Morning sluggishness or vivid dreamsCommunity reported
Important limitation: No controlled incidence.
ImmunogenicityRegulatory concern
Important limitation: Theoretical aggregation-related risk.
Sedative interactionsUnknown
Important limitation: No formal interaction studies.
Product qualityPractical risk
Important limitation: Unapproved research material.
Long-term effectsUnknown
Important limitation: No reliable follow-up.
DSIP Timeline and Monitoring
Four to seven nights
Published short-course study window.
Four to eight weeks
Community cycle range; not clinically validated.
Long term
No reliable outcome or safety data.
DSIP Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Sleep duration or efficiency | Mixed small human evidence | 1980s studies | No modern confirmation |
| Daytime function | Limited small-study signal | Insomnia populations | Needs replication |
| Withdrawal symptoms | Very limited reports | Open-label or case-series context | Not established |
| Stress or pain modulation | Preclinical/limited | Mechanistic research | No approved claim |
DSIP Storage and Handling
Unreconstituted vial
No independently verified DSIP-vial stability duration was identified.
Prepared vial
Community refrigeration guidance is not validated product-specific stability evidence.
Freeze-thaw
Product-specific effects are not established.
Appearance
Cloudiness or discoloration cannot establish the source of a problem.
DSIP Troubleshooting
IV and SC amounts conflict
They use different routes and units and cannot be converted into a regimen.
Sleep does not improve
Human findings were mixed and efficacy is not established.
Units look wrong
Recheck vial mg, liquid mL, target mg, and U-100 conversion.
Product testing is pending
Do not describe the current batch as verified.
A scheduled amount is missed
No validated missed-dose procedure exists.
DSIP Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| DSIP | Sleep-associated nonapeptide | Small older mixed trials | Not approved |
| Melatonin | Circadian hormone | Broader human evidence | OTC supplement in U.S. |
| Benzodiazepines | GABA-A medicines | Approved indications | Not interchangeable |
| Epitalon | Tetrapeptide bioregulator | Primarily preclinical | Not approved |
DSIP Frequently Asked Questions
What is DSIP?
A nine-amino-acid peptide also called emideltide.
Is it FDA approved?
No.
Does it have human research?
Yes, but studies are small, old, and mixed.
What route did human trials use?
Intravenous administration.
Is subcutaneous use validated?
No; it is community reported.
What is its half-life?
Not established.
Does DSIP reliably improve sleep?
No; older findings were inconsistent.
Are four-to-eight-week cycles proven?
No.
Is long-term safety known?
No.
What does the calculator do?
It performs concentration and volume arithmetic only.
Sources and Research
Coverage source
1. DSIP protocol coverage source
Separates older IV trials from community SC schedules.
Open direct sourceHuman research
2. DSIP in chronic insomnia
Small double-blind matched-pairs human sleep study.
Open direct sourceHuman research
3. Short-term DSIP in chronic insomnia
Double-blind crossover study using 25 nmol/kg IV.
Open direct sourceHuman research
4. Acute and delayed DSIP effects
Six-volunteer double-blind crossover study.
Open direct sourceMissing information flagged for review
- Modern confirmatory trial: Not established
- Validated SC dose and route: Not established
- Human SC pharmacokinetics: Not established
- Human half-life: Not established
- Validated cycle and rest period: Not established
- Product-specific stability: Not established
- Long-term safety and interactions: Not established